Rodríguez-Otero, Paula
Mateos, María Victoria
Martínez-López, Joaquín
Hernández, Miguel-Teodoro
Ocio, Enrique M.
Rosiñol, Laura
Martínez, Rafael
Teruel, Ana-Isabel
Gutiérrez, Norma C.
Bargay, Joan
Bengoechea, Enrique
González, Yolanda
de Oteyza, Jaime Pérez
Gironella, Mercedes
Nuñez-Córdoba, Jorge M.
Encinas, Cristina
Martín, Jesús
Cabrera, Carmen
Palomera, Luis
de Arriba, Felipe
Cedena, María Teresa
Puig, Noemí
Oriol, Albert
Paiva, Bruno
Bladé, Joan
Lahuerta, Juan José
San Miguel, Jesús F.
Funding for this research was provided by:
Has declared consultancy for: Janssen, Celgene, Takeda, Amgen
Consultancy for or honoraria from: Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, BMS, Janssen
Has served as a member of advisory boards for Janssen and Celgene.
Has declared grants from Celgene, EngMab, Sanofi and Takeda, and received honoraria for lectures and advisory boards from Amgen, BMS, Celgene, Janssen, Takeda, Sanofi, and Novartis.
Article History
Received: 13 September 2018
Revised: 28 December 2018
Accepted: 14 January 2019
First Online: 18 March 2019
Conflict of interest
: P.R.-O.: has served on the speaker’s bureau and as a member of advisory boards for Janssen, Celgene, BMS, and Takeda. M.V.M.: has declared consultancy for: Janssen, Celgene, Takeda, and Amgen. E.M.O.: has declared consultancy for or honoraria from: Mundipharma, Celgene, Amgen, Novartis, Takeda, AbbVie, BMS, and Janssen. B.P.: has declared grants from Celgene, EngMab, Sanofi, and Takeda, and received honoraria for lectures and advisory boards from Amgen, BMS, Celgene, Janssen, Takeda, Sanofi, and Novartis. J.F.S.M.: received honoraria as part of Advisory boards from Celgene, Novartis, Millenium, Janssen, Amgen, MSD, Sanofi, and BMS. A.O.: has served as a member of advisory boards for Janssen and Celgene. J.B.: received honoraria for lectures and advisory boards from Celgene and Janssen and grant support from Janssen. L.R.: received honoraria from Janssen and Celgene. The remaining authors declare that they have no conflict of interest.